<DOC>
	<DOCNO>NCT01190215</DOCNO>
	<brief_summary>This study design assess immunogenicity , reactogenicity safety follow vaccination GSK Biologicals ' FluarixTM vaccine child previously vaccinate one dose PandemrixTM age 10-17 year .</brief_summary>
	<brief_title>Immunogenicity Safety Study FluarixTM Vaccine Children Who Have Previously Been Vaccinated With PandemrixTM</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects previously immunize one single dose Pandemrix age 1017 year inclusive . Subjects receive Pandemrix least six month prior study enrolment . Subjects investigator believe subject and/or parent ( ) /Legally Acceptable Representative ( ) [ LAR ( ) ] comply requirement protocol Written inform consent obtain subject/ parent ( ) /LAR ( ) subject . Healthy subject establish medical history clinical examination enter study . Subjects Parent ( ) /LAR ( ) access consistent mean telephone contact , land line mobile , NOT pay phone multipleuser device Active participation clinical trial . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine plan use study period . Planned administration vaccine 30 day prior 30 day study vaccine administration . Chronic administration immunosuppressant immunemodifying drug within three month prior enrolment study plan administration study period . Acute disease and/or fever time enrolment : Acute chronic , clinicallysignificant pulmonary , cardiovascular , hepatic renal functional abnormality , determine medical history physical examination . Administration immunoglobulins and/or blood product within three month prior enrolment study , plan use study . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination Any know suspect allergy constituent influenza vaccine ; history anaphylactictype reaction constituent influenza vaccine ; history severe adverse reaction previous influenza vaccine . History seizures progressive neurological disease . Subjects receive H1N1v pandemic vaccine Pandemrix receive 2010/2011 seasonal influenza vaccine . If subject female childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution two month completion vaccination series . Child care .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Pandemrix</keyword>
	<keyword>H1N1</keyword>
	<keyword>Fluarix</keyword>
</DOC>